Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Contact

Abraxis BioScience, Inc.
Investors and Media:
Christine Cassiano, 310-405-7417
or
Media:
Claire Campbell, 908-393-8238


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:5/16/2008)...- BioVex Inc, a biotechnology,company...d infectious,disease, announced today that the abs...e II clinical trial of OncoVEX GM-CSF in advanced ...an Society of Clinical Oncology,(ASCO) website loc...stract,which describes the data as of the submissi...
(Date:5/16/2008)...s First-Ever PEGylation of a Small Molecule with ..., SAN CARLOS, Calif., May 16 /PRNewswire-FirstCal...ed initial results today from a Phase 1,study of N...nificant,anti-tumor activity in patients with refr...hat Nektar,s small molecule PEGylation technology,...
(Date:5/16/2008)...- Veridex, LLC announced today that,i...of America Holdings,(LabCorp), has commercially la...ncer. The new assay uses the biological specificit...ng the methylation of the gene,GST-Pi. Methylation...,cancer. Veridex is developing the methylation mar...
(Date:5/16/2008)...atistically Significant Reductions in Selected ...act to be published in 2008 Proceedings of the Ame...l Oncology, SAN DIEGO, May 16 /PRNewswire-FirstCa...) announced today that, in a registrational bioequ...atistically significant reduction,in general disor...
Breaking Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2905 1MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2905 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2905 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2905 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2905 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2905 6Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 1Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 3Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 4Dako Selects Axeda for Remote Monitoring Reporting and Software Management of Cancer Diagnostic System 10625 1Dako Selects Axeda for Remote Monitoring Reporting and Software Management of Cancer Diagnostic System 10625 2Christopher and Dana Reeve Foundation Awards Nearly 242 Million in Individual Research Grants 2903 1Christopher and Dana Reeve Foundation Awards Nearly 242 Million in Individual Research Grants 2903 2Christopher and Dana Reeve Foundation Awards Nearly 242 Million in Individual Research Grants 2903 3
...e/ -- Data presented,today at a major medical meet...ets administered once-daily for five days is as,ef...500 mg) for 10,days for the treatment of complicat...nephritis (AP). , Ortho-McNeil, Inc., the company ...ata during a scientific session at the annual,meet...
...% 3.5 Years Post Surgery, VIENNA, Va., May 21, 200...nounced today that its cancer drug Multikine(R) wa...l survival in a,Phase II study of head and neck ca...2007 at the First International Congress of,the In...dam, the,Netherlands, by Dr. Eyal Talor, Senior VP...
Other Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4CEL-SCI Presents Long-Term Cancer Survival Data With Multikine 2CEL-SCI Presents Long-Term Cancer Survival Data With Multikine 3
(Date:5/16/2008)...cal trials presented by Calpis Co., Ltd. at the Am...Annual Scientific Meeting and Exposition (ASH 2008...y supplement AmealPeptide reduces blood pressure i...D (Achieve Hypertension Efficacy with AmealPeptide...tive, Two-phase Randomized, Open-Label, Blinded En...
(Date:5/16/2008)... -- Superior launch strategies,allow best-in-class...,crowded markets. To secure "share of voice" for a...ptake strategies to support business needs and,ens...l companies achieve,attention in the market during...., "Best Practices for Winning Product Launch Suc...
(Date:5/16/2008)...d Information Technology That, Optimizes Cardiolo...ases Efficiency, SE...ced clinical and,information technology (IT) for t...www.siemens.com/healthcare ) will demonstrate the ...iology and cardiology workflow and image,processin...
(Date:5/16/2008)...PRNewswire-FirstCall/ -- BMP,Sunstone Corporation ...and,distribution pharmaceutical companies, today a...owing conferences:, (1) The Roth Annual China D...David Gao, Chief Executive Officer of the Company,... 2008, at 4:40 pm local time at the Regent Ho...
Breaking Medicine News(10 mins):Health News:Calpis' AmealPeptide lowers blood pressure in 2 placebo-controlled trials 2Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 3Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 4Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 5Health News:BMP Sunstone Announces Participation in May Investor Conferences 2
...ers from Tufts University in Boston, eating three ...d substantially reduce the risk of developing type... ate an average of 3.5 servings of whole grains pe...s than a half a serving of whole grains// per day....
...n in a new study, that soy can lower cholesterol a...h the two new studies give more reason to dish up ...in and omega 3 fatty acids, which are found in abu...have been enhanced for their health benefits. But ...
... that children with sleep-disordered breathing suf... addition, the study shows a tremendous improvemen...on. Between 2 percent and 6 percent of preschool a...tructive sleep apnea, or upper airway obstruction....
... study, infants as young as even 3 days old can te...Teresa Farroni, study's lead author, doubts that h...very early in life as a survival necessity. Farron...ognitive Development in the School of Psychology a...
Other Medicine News:Health News:Soy, Omega 3s convalesce artery health 2Health News:Soy, Omega 3s convalesce artery health 3Health News:Tonsillectomy improves quality of life 2Health News:Newborns Know how to make eye contact 2
This dissector offers dual-action jaws, which are long, tapered, and angled 30 to simplify even difficult laparoscopic dissection.
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs.
Insulated, angled, spoon-shaped design cups the gallbladder, permits clear visualization, and allows easy dissection and control of bleeders.
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes.
Medicine Products: